



Synthesis and in-vitro antioxidant and antitumor evaluation of novel pyrazole-based heterocycles


Mahmoud F. Ismail¹ · Amira A. El-sayed¹

Received: 18 August 2018 / Accepted: 30 November 2018
© Iranian Chemical Society 2018

Abstract

Hydrazide-hydrazone, namely, *N'*-((5-chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene)-2-cyanoacetohydrazide **3**, was utilized as a key starting material for the construction of a variety of novel heterocyclic moieties. The newly synthesized compounds were characterized by elemental analyses and spectral data (IR, ¹H-NMR, and mass spectra). Some of the newly synthesized compounds were screened for their antitumor and antioxidant activities. The results showed clearly that compounds **6**, **11**, **13**, **22**, and **29** displayed promising in-vitro antitumor activity against two cell lines (HepG2 and MCF-7). Among these compounds, compounds **13** and **29** exhibited the highest activity as antitumor agents. On the other hand, compounds **13**, **22**, and **29** exhibited the highest inhibitory antioxidant activity using ABTS method. While, in case of erythrocytes hemolysis, compounds **4**, **13**, and **29** proved to exhibit potent antioxidative activity as vitamin C. Meanwhile, compounds **6**, **11**, **16**, **21**, and **22** showed a remarkable promising activity. In light of the highest potency of our novel compounds in targeting both antitumor and antioxidant activities, compounds **13** and **29** warrant persistent preclinical development as antitumor and antioxidant agents.

Graphical abstract



Keywords Pyrazole · Diarylidene hydrazine · Iminocoumarin · 1,3-Thiazole · Antioxidant · Antitumor

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s13738-018-1566-x>) contains supplementary material, which is available to authorized users.

Extended author information available on the last page of the article

Introduction

The pyrazole nucleus is a ubiquitous feature of a pharmacophoric scaffold, which represents a class of heterocyclic compounds with a wide range of biological applications. Many of them are widely used as potent analgesic, antiarrhythmic and anticonvulsant [1], antidiabetic [2], anticancer [3], anti-inflammatory [4, 5], anti-conceptive and antipyretic [6], muscle relaxing [7], antifungal [8, 9], antibacterial activities [8], insecticidal [10], herbicidal [11], anti HIV, antagonist of OPL1, BACE inhibitors for the treatment of Alzheimer's disease, hepatitis C virus, and hypoxia inducible factor [12].

After profound investigation, various methods are available for the synthesis of the pyrazole moiety such as utility of the catalytic performance of $\text{Fe}_3\text{O}_4\text{@HNTs-PEI}$ [13], utility of a cellulose-based nanobiocomposite decorated with Fe_3O_4 nanoparticles in water as a green solvent at ambient temperature [14], and via multicomponent reactions (MCRs) are powerful synthetic tools [15].

From synthetic aspect, since cyanoacetohydrazide derivatives possess both electrophilic and nucleophilic properties [16]. They have been used to design diverse heterocyclic moieties such as pyrazole, 1,3-dithiolane, thiadiazole, 1,3-thiazolidinone, iminocoumarin, and pyridazine derivatives [17–19].

Due to all of the aforementioned facts and in continuation our previous work, *N'*-((5-chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene)-2-cyanoacetohydrazide **3** as a readily available precursor for the synthesis of such new heterocyclic systems which might show pharmacological effects.

Experimental

Chemistry

General information

Melting points are uncorrected and were determined in open capillary tubes using an electric melting point apparatus (G-K). The IR spectra ($400\text{--}4000\text{ cm}^{-1}$) were recorded on the Nicolet iS10 FT-IR spectrometer using KBr Wafer technique. ^1H -NMR spectrum was recorded with a Varian Gemini spectrometer at 400 MHz with TMS as the internal standard and chemical shifts were reported on a δ scale (ppm) using CDCl_3 or DMSO-d_6 as solvents, while the coupling constants (*J* values) are given in Hz. Elemental analyses (C, H, N, and S) were carried out at the Microanalytical Data Centre at the Faculty of Science, Cairo University, Egypt. Mass spectra were performed

on Shimadzu GC-MS QP1000EX apparatus in central analytical lab, Ain Shams University. All reactions were monitored by TLC (thin layer chromatography, Merck) and spots were detected using a UV lamp (254 nm). Biological activity was tested at the drugs department, Faculty of pharmacy, Mansoura University, Egypt.

N'-((5-Chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene)-2-cyanoacetohydrazide **3**

A mixture of 5-chloro-3-methyl-1-phenyl-1*H*-pyrazole-4-carbaldehyde **1** (2.2 g, 0.01 mol) and cyanoacetohydrazide **2** (0.99 g, 0.01 mol) in absolute ethanol and/or dioxane (30 ml) was heated under reflux for 4 h. The pale yellow solid which separated after slow evaporation was collected by filtration and then recrystallized from ethanol to give **3** as pale yellow crystals; m.p.: 190 °C, yield: 87%. IR (KBr): 3192, 3126 (NH), 2961, 2922, 2876 (CH_2 , CH_3), 2263 ($\text{C}\equiv\text{N}$), 1681 ($\text{C}=\text{O}$), 1646, 1618 ($\text{C}=\text{N}$) cm^{-1} . ^1H NMR (400 MHz, DMSO-d_6) δ (ppm): 7.57–7.47 (m, 5H, Ar-H), for anti-isomer [11.69 (s, 1H, NH, exchangeable with D_2O), 7.96 (s, 1H, $\text{HC}=\text{N}$), 4.12 (s, 2H, CH_2CN), 2.41 (s, 3H, CH_3)], for syn-isomer [11.63 (s, 1H, NH, exchangeable with D_2O), 8.13 (s, 1H, $\text{HC}=\text{N}$), 3.76 (s, 2H, CH_2CN), 2.04 (s, 3H, CH_3)]. MS *m/z* (%): 301 (M^+ ; 10.4), 265 (11.7), 141 (5.0), 128 (33.8), 118 (19.0), 77 (100), 51 (24.2). Anal. Calcd. for $\text{C}_{14}\text{H}_{12}\text{ClN}_5\text{O}$ (301.73): C 55.73; H 4.01; Cl 11.75; N 23.21. Found: C 55.71; H 3.99; Cl 11.74; N 23.18.

1,2-Bis((5-chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene)hydrazine **4**

Method A A mixture of 5-chloro-3-methyl-1-phenyl-1*H*-pyrazole-4-carbaldehyde **1** (2.2 g, 0.01 mol) and cyanoacetohydrazide **2** (0.99 g, 0.01 mol) in ethanol (30 ml) containing drops of piperidine was heated under reflux for 2 h. The light brown solid which separated after cooling was collected by filtration and then recrystallized from ethanol to give **4**, yield: 79%.

Method B Compound **3** (0.5 g, 1.7 mmol) was heated under reflux in pyridine (10 ml) for 4 h. The light brown solid which separated after cooling was collected by filtration and then recrystallized from ethanol to give **4**, yield: 44%.

Method C A mixture of compound **3** (0.5 g, 1.7 mmol) and anhydrous potassium carbonate (1.38 g, 0.01 mol) in dry acetone (30 ml) was heated under reflux in water bath for 24 h. After cooling, poured onto cooled water to afford light

brown solid that was recrystallized from ethanol to give **4**, yield: 41%.

Method D A mixture of **3** (1.0 g, 3.3 mmol) and hydrazine monohydrate (0.16 ml 3.3 mmol) in dioxane (20 ml) was heated under reflux for 3 h. After cooling, the solid deposited was collected by filtration and recrystallized from ethanol to give **4**, yield: 67%.

Method E A mixture of **9** (1.0 g, 2.3 mmol) and hydrazine monohydrate (0.12 ml, 2.3 mmol) in ethanol (20 ml) was heated under reflux for 3 h. After slow evaporation, pour onto acidified cold water, the solid deposited was collected by filtration and recrystallized from ethanol to give **4**, yield: 64%.

Method F A mixture of **23** (1.0 g, 2.2 mmol) and hydrazine monohydrate (0.11 ml, 2.2 mmol) in ethanol (20 ml) was heated under reflux for 3 h. After slow evaporation, the solid deposited was recrystallized from ethanol to give **4**, yield: 61%.

4: As buff crystals; m.p.: 250 °C. IR (KBr): 2998, 2932 (CH₃), 1632 (C=N) cm⁻¹. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.57 (s, 2H, HC=N), 7.62–7.51 (m, 10H, Ar-H), 2.51 (s, 6H, 2CH₃). MS m/z (%): 217 (M⁺-C₁₁H₉ClN₃; 100), 182 (62.4), 156 (52.1), 141 (33.7), 105 (11.9) 77 (55.9), 55 (23.8). Anal. Calcd. for C₂₂H₁₈Cl₂N₆ (437.33): C 60.42; H 4.15; Cl 16.21; N 19.22. Found: C 60.40; H 4.16; Cl 16.23; N 19.19.

5'-Chloro-3'-methyl-5-oxo-1'-phenyl-2,5-dihydro-1H,1'H-[3,4'-bipyrazole]-4-carbonitrile 5 and 5'-chloro-3'-methyl-5-oxo-1'-phenyl-4,5-dihydro-1H,1'H-[3,4'-bipyrazole]-4-carbox amide 6 (as lactam-lacim tautomer)

Method A Compound **1** (0.5 g, 2.3 mmol) and cyanoacetohydrazide **2** (0.23 g, 2.3 mmol) are mixed together in absolute ethanol (15 ml) containing few drops of glacial acetic acid (0.5 ml). The reaction mixture was refluxed for 10 h and left to cool, the solid formed was filtered and then recrystallized from ethanol to give **5**, yield: 73%.

Method B Compound **3** (0.5 g, 1.7 mmol) was heated under reflux in pyridine (10 ml) for 4 h. The light brown solid which separated after cooling was collected by filtration and then recrystallized from ethanol to give **4**. After acidification of the mother liquor, the solid deposited was filtrate and then recrystallized from ethanol to give **5**, yield: 31%.

Method C Compound **3** (0.5 g, 1.7 mmol) was heated under reflux in glacial acetic acid (10 ml) for 10 h. The reaction mixture was then partially evaporated and left

to precipitate, the product obtained was filtered and then recrystallized from benzene to give **6**, yield 33%, while the insoluble fractional in benzene was recrystallized from ethanol to afford **5**, yield: 46%.

5: As brown crystals; m.p.: >360 °C. IR (KBr): 3374, 3217 (NH), 2927, 2857 (CH₃), 2213 (C≡N), 1672 (C=O) cm⁻¹. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 11.82 (br.s, 1H, NH, exchangeable with D₂O), 11.19 (br.s, 1H, NH, exchangeable with D₂O), 7.81–7.24 (m, 5H, Ar-H), 2.20 (s, 3H, CH₃). MS m/z (%): 299 (M⁺; 16.1), 217 (13.2), 188 (100), 182 (9.0), 174 (35.9), 105 (25.7), 91 (33.8), 77 (64.9). Anal. Calcd. for C₁₄H₁₀ClN₅O (299.72): C 56.10; H 3.36; Cl 11.83; N 23.37. Found: C 56.08; H 3.34; Cl 11.86; N 23.39.

6 (As lactam–lactim tautomer): as orange crystals; m.p.: 210–211 °C. IR (KBr): 3418, 3294, 3120 (NH₂, NH), 2926, 2850 (CH, CH₃), 1687, 1641 (C=O) cm⁻¹. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 13.31 (s, 1H, OH, exchangeable with D₂O for lactim tautomer), 12.20 (s, 2H, NH₂, exchangeable with D₂O for lactam tautomer), 10.65 (s, 1H, NH, exchangeable with D₂O for lactam tautomer), 10.40 (s, 2H, NH₂, exchangeable with D₂O for lactim tautomer), 7.69 (d, 2H, Ar-H, *J* = 8.8 Hz), 7.50 (t, 2H, Ar-H, *J* = 7.6, *J* = 8.4 Hz), 7.34–7.28 (m, 1H, Ar-H), 3.46 (s, 1H, CHCO), 2.15, 2.05 (2 s, 3H, CH₃). MS m/z (%): 317 (M⁺; 15.0), 316 (71.3), 299 (25.0), 281 (100), 274 (8.1), 265 (27.3), 77 (91.1), 51 (30.2). Anal. Calcd. for C₁₄H₁₂ClN₅O₂ (317.73): C 52.92; H 3.81; Cl 11.16; N 22.04. Found: C 52.92; H 3.83; Cl 11.13; N 22.01.

N'-((5-Chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene)-2-cyano-3-(4-nitrophenyl)acrylohydrazide 9 (as lactam-lacim tautomer)

A mixture of **3** (1.0 g, 3.3 mmol), *p*-nitrobenzaldehyde (0.50 g, 3.3 mmol) and sodium ethoxide (15 ml) in absolute ethanol (20 ml) was stirred at ambient temperature for 4 h. The resulting mixture was acidified with cold dilute acetic acid. The precipitated solid was filtered off, washed several times with cold water, and recrystallized from ethanol to give **9** as yellow crystals; m.p.: 216–218 °C, yield: 71%. IR (KBr): 3273, 3194 (NH), 2962, 2923, 2854 (CH₃), 2210 (C≡N), 1680, 1668 (C=O), 1626 (C=N), 1604 (C=C), 1529, 1346 (NO₂) cm⁻¹. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 11.60 (s, 1H, OH, exchangeable with D₂O for lactim tautomer), 8.57 (s, 1H, NH, exchangeable with D₂O for lactam tautomer), 8.47 (s, 1H, HC=N), 8.24–8.22 (d, 2H, Ar-H, *J* = 8.4 Hz), 8.01 (s, 1H, HC_(olefinic)), 7.73–7.71 (d, 2H, Ar-H, *J* = 8.4 Hz), 7.59–7.49 (m, 5H, Ar-H), 2.51 (s, 3H, CH₃). MS m/z (%): 434 (M⁺; 4.4), 342 (100), 324 (16.0), 316 (27.5), 299 (7.7), 281 (5.4), 265 (10.5), 77 (57.9). Anal. Calcd. for C₂₁H₁₅ClN₆O₃ (434.84): C 58.01; H 3.48; Cl 8.15; N 19.33. Found: C 57.97; H 3.46; Cl 8.13; N 19.36.

N'*-((5-Chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene)-2-cyano-2-(2-oxoindolin-3-ylidene)acetohydrazide **11*

A mixture of **3** (1.0 g, 3.3 mmol), isatin (0.49 g, 3.3 mmol), and piperidine (0.5 ml) in absolute ethanol (20 ml) was heated under reflux for 4 h. After cooling, the solid deposited was collected by filtration, and recrystallized from ethanol to give **11** as dark brown crystals; m.p.: 284–285 °C, yield: 53%. IR (KBr): 3273, 3194 (NH), 2961, 2923, 2876 (CH₃), 2202 (C≡N), 1728, 1680 (C=O), 1621 (C=N), 1604 (C=C) cm⁻¹. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 12.35 (br.s, 1H, NH, exchangeable with D₂O), 11.26 (br.s, 1H, NH, exchangeable with D₂O), 8.55 (d, 1H, Ar-H_{indolinone}, *J* = 10 Hz), 8.52 (s, 1H, HC=N), 7.67–7.49 (m, 5H, Ar-H), 7.43 (d,d, 1H, Ar-H_{indolinone}, *J* = 8.4 Hz), 7.31 (t, 1H, Ar-H_{indolinone}, *J* = 7.6, *J* = 7.2 Hz), 6.88 (d, 1H, Ar-H_{indolinone}, *J* = 8 Hz), 2.60 (s, 3H, CH₃). MS *m/z* (%): 431 (M⁺ + 1; 13.6), 395 (25.6), 217 (100), 183 (19.7), 77 (57.9). Anal. Calcd. for C₂₂H₁₅ClN₆O₂ (430.85): C 61.33; H 3.51; Cl 8.23; N 19.51. Found: C 61.35; H 3.49; Cl 8.21; N 19.53.

1-(((5-Chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene)amino)-4,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonitrile **12**

A mixture of **3** (0.3 g, 1 mmol) and acetylacetone (0.10 ml, 1 mmol) in ethanol (15 ml) containing a few drops of piperidine (four drops) was refluxed for 6 h. After cooling, the reaction mixture was acidified with cold dilute acetic acid. The solid that separated out was filtered off, washed several times with cold water and recrystallized from ethanol to give **12** as buff crystals; m.p.: 243–245 °C, yield: 55%. IR (KBr): 2999, 2928, 2849 (CH₃), 2215 (C≡N), 1651 (C=O), 1591 (C=N) cm⁻¹. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 8.76 (s, 1H, HC=N), 7.62–7.51 (m, 5H, Ar-H), 6.39 (s, 1H, CH_{pyridinone}), 2.47 (s, 3H, CH_{3pyrazole}), 2.346 (s, 3H, CH_{3pyridinone}), 2.343 (s, 3H, CH_{3pyridinone}). MS *m/z* (%): 365 (M⁺; 5.8), 218 (51.2), 183 (27.3), 156 (16.8), 77 (100), 51 (28.6). Anal. Calcd. for C₁₉H₁₆ClN₅O (365.82): C 62.38; H 4.41; Cl 9.69; N 19.14. Found: C 62.35; H 4.43; Cl 9.66; N 19.10.

6-Amino-1-(((5-chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene)amino)-4-(3,4-dimethoxyphenyl)-2-oxo-1,2,3,4-tetrahydropyridine-3,5-dicarbonitrile **13**

A mixture of **3** (0.3 g, 1 mmol), 2-(3,4-dimethoxybenzylidene)malononitrile (0.21 g, 1 mmol) in absolute ethanol (15 ml) containing few drops of piperidine (four drops) was heated under reflux for 6 h. After evaporation of the solvent in *vacuo*, the solid obtained was collected and recrystallized from benzene to give **13** as reddish brown crystals;

m.p.: 192–194 °C, yield: 61%. IR (KBr): 3341, 3216 (NH₂), 2935, 2837 (CH₃), 2212 (C≡N), 1676 (C=O), 1628 (C=N), 1606 (C=C) cm⁻¹. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 8.25 (br.s, 2H, NH₂, exchangeable with D₂O), 7.79 (s, 1H, HC=N), 7.65–7.50 (m, 5H, Ar-H), 7.34 (s, 1H, Ar-H), 7.08–7.06 (d, 2H, Ar-H), 3.85 (s, 3H, OCH₃), 3.82 (s, 3H, OCH₃), 3.79–3.77 (d, 1H, COCHCN, *J* = 6.8 Hz), 3.69–3.67 (d, 1H, CHAr, *J* = 8 Hz), 2.27 (s, 3H, CH₃). MS *m/z* (%): 343 (M⁺ - [C₆H₃(OMe)₂ + Cl]; 17.1), 341 (100), 327 (15.3), 301 (3.4), 77 (28.8). Anal. Calcd. for C₂₆H₂₂ClN₇O₃ (515.96): C 60.53; H 4.30; Cl 6.87; N 19.00. Found: C 60.55; H 4.31; Cl 6.85; N 18.98.

N'*-((5-Chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene)-2-imino-2*H*-chromene-3-carbohydrazide **15a*

A mixture of **3** (1.0 g, 3.3 mmol) and salicylaldehyde **14a** (0.35 ml, 3.3 mmol) in absolute ethanol (20 ml) in the presence of piperidine (0.5 ml) was heated under reflux for 3 h. After cooling, the solid deposited was collected by filtration and recrystallized from ethanol to give **15a** as light yellow crystals; m.p.: 210–211 °C, yield: 85%. IR (KBr): 3312 (NH), 2958, 2921, 2854 (CH₃), 1682 (C=O), 1632 (C=N), 1617 (C=C) cm⁻¹. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 13.46 (s, 1H, NH, exchangeable with D₂O), 9.17 (s, 1H, NH, exchangeable with D₂O), 8.49 (s, 1H, HC=C), 8.29 (s, 1H, HC=N), 7.81 (d, 1H, Ar-H, *J* = 7.6 Hz), 7.59–7.49 (m, 7H, Ar-H), 7.29–7.23 (d,d, 1H, Ar-H, *J* = 7.6, *J* = 8.4 Hz), 2.65 (s, 3H, CH₃). MS *m/z* (%): 339 (M⁺ - C₄H₂O; 23.6), 338 (100), 321 (32.6), 303 (44.9), 261 (2.8), 218 (14.7), 217 (22.0), 182 (15.0), 155 (9.6), 128 (14.9), 77 (46.9). Anal. Calcd. for C₂₁H₁₆ClN₅O₂ (405.84): C 62.15; H 3.97; Cl 8.73; N 17.26. Found: C 62.19; H 3.98; Cl 8.71; N 17.24.

N'*-((5-Chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene)-2-imino-6,8-dinitro-2*H*-chromene-3-carbohydrazide **15b*

A mixture of **3** (1.0 g, 3.3 mmol) and 3,5-dinitrosalicylaldehyde **14b** (0.7 g, 3.3 mmol) in absolute ethanol (20 ml) in the presence of piperidine (0.5 ml) was heated under reflux for 3 h. After cooling, the solid deposited was collected by filtration and recrystallized from dioxane to give **15b** as yellow crystals; m.p.: 248 °C, yield: 88%. IR (KBr): 3206 (NH), 2962, 2926, 2863 (CH₃), 1683 (C=O), 1619 (C=N), 1550, 1339 (NO₂) cm⁻¹. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 11.81 (s, 1H, NH, exchangeable with D₂O), 8.98 (s, 1H, NH, exchangeable with D₂O), 8.50 (s, 1H, Ar-H), 8.30 (s, 1H, HC=C), 8.19 (s, 1H, HC=N), 8.13 (s, 1H, Ar-H), 7.59–7.47 (m, 5H, Ar-H), 2.45 (s, 3H, CH₃). MS *m/z* (%): 219 (M⁺ - C₁₀H₄N₄O₆;

100), 156 (13.3), 77 (25.6), 51 (12.6). Anal. Calcd. for $C_{21}H_{14}ClN_7O_6$ (495.84): C 50.87; H 2.85; Cl 7.15; N 19.77. Found: C 50.89; H 2.82; Cl 7.17; N 19.79.

N*-(3-(2-((5-Chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene)hydrazine-1-carbonyl)-2*H*-chromen-2-ylidene)formamide **16*

A solution of compound **15a** (0.25 g, 0.62 mmol) in a mixture of triethylorthoformate (5 ml) and acetic anhydride (5 ml) was heated under reflux for 3 h. After cooling, the yellow precipitated was collected by filtration and recrystallized from toluene to give **16** as yellow crystals; m.p.: 241–243 °C, yield: 65%. IR (KBr): 3209 (NH), 2958, 2923, 2854 (CH_3), 1710 ($C=O_{aldehyde}$), 1677 ($C=O_{amide}$), 1616 ($C=N$) cm^{-1} . 1H NMR (400 MHz, DMSO- d_6) δ (ppm): 11.69 (s, 1H, NH, exchangeable with D_2O), 8.83 (s, 1H, CHO), 8.43 (s, 1H, $HC=C$), 8.27 (s, 1H, $HC=N$), 7.98(d, 1H, Ar-H, $J=7.6$ Hz), 7.80–7.74 (d,d, 1H, Ar-H, $J=8.4$, $J=8.4$ Hz) 7.60–7.50 (m, 5H, Ar-H), 7.47–7.45 (d, 1H, Ar-H, $J=7.6$ Hz), 7.43–7.37 (d,d, 1H, Ar-H, $J=8.4$, $J=7.6$ Hz), 2.43 (s, 3H, CH_3). MS m/z (%): 432 ($M^+ - 1$; 11.7), 362 (27.1), 217 (100), 77 (54.3). Anal. Calcd. for $C_{22}H_{16}ClN_5O_3$ (433.85): C 60.91; H 3.72; Cl 8.17; N 16.14. Found: C 60.93; H 3.69; Cl 8.14; N 16.17.

N*-(3-(2-((5-Chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene)hydrazine-1-carbonyl)-6,8-dinitro-2*H*-chromen-2-ylidene)formamide **17a** and 3-(((5-chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene)amino)-2-ethoxy-7,9-dinitro-2,3-dihydro-4*H*-chromeno[2,3-*d*]pyrimidin-4-one **17b*

A solution of compound **15b** (0.25 g, 0.51 mmol) in a mixture of triethylorthoformate (5 ml) and acetic anhydride (5 ml) was heated under reflux for 3 h. After cooling, the solid deposited was collected by filtration and recrystallized from toluene to give **17a,b** as yellow crystals; m.p.: 203–205 °C, yield: 67%.

IR (KBr): 3443 (NH), 2973, 2927, 2861 ($C-H_{aliph}$), 1719 ($C=O_{aldehyde}$), 1678 ($C=O_{amide}$), 1631 ($C=N$), 1613 ($C=C$), 1528, 1346 (NO_2) cm^{-1} . 1H NMR (400 MHz, DMSO- d_6) δ (ppm):

17a: 9.03 (s, 1H, CHO), 8.79 (s, 1H, Ar-H), 8.72 (s, 1H, NH, exchangeable with D_2O), 8.59 (s, 1H, $HC=C$), 8.48 (s, 1H, $HC=N$), 8.32 (s, 1H, Ar-H), 7.67–7.52 (m, 5H, Ar-H), 2.51(s, 3H, CH_3).

17b: 8.69 (s, 1H, Ar-H), 8.58 (s, 1H, $HC=C$), 8.41 (s, 1H, $HC=N$), 8.30 (s, 1H, Ar-H), 7.67–7.52 (m, 5H, Ar-H), 5.83 (s, 1H, $CH_{pyrimidinone}$), 3.66–3.56 (q, 2H, CH_2CH_3 , $J=7.2$ Hz), 2.50 (s, 3H, CH_3), 1.03–1.00 (t, 3H, CH_2CH_3 , $J=6.8$ Hz).

GC-MS: 2 peaks; 1st peak; percentage = 16.88%; MS m/z (%): 219 ($M^+ - C_{11}H_5N_4O_7$; 100), 217 (8.2), 182 (5.4), 155 (20.7), 143 (6.2), 77 (37.0), 51 (17.6).

2nd peak; percentage = 83.12%; MS m/z (%): 219 ($M^+ - C_{13}H_9N_4O_7$; 92.8), 217 (100), 182 (100), 155 (70.5), 141 (100), 114 (29.5), 77 (100), 51 (68.3).

4-Amino-*N'*-((5-chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene)-3-phenyl-2-thioxo-2,3-dihydrothiazole-5-carbohydrazide **18**

To a solution of compound **3** (3.01 g, 0.01 mol) in ethanol (30 ml) containing triethylamine (0.5 ml), elemental sulfur (0.32 g, 0.01 mol) and phenyl isothiocyanate (1.2 ml, 0.01 mol) were added. The reaction mixture was heated at 60 °C for 1 h with continuous stirring. The grey solid deposited, while hot was collected by filtration, washed several times with ethanol and recrystallized from toluene to give **18** as buff crystals; m.p.: 261–262 °C, yield: 80%. IR (KBr): 3382, 3247, 3178 (NH_2 , NH), 2958, 2925, 2857 (CH_3), 1632 ($C=O$), 1602 ($C=N$), 1242 ($C=S$) cm^{-1} . 1H NMR (400 MHz, $CDCl_3$) δ (ppm): 8.52 (br.s, 1H, NH, exchangeable with D_2O), 7.74 (s, 1H, $HC=N$), 7.66–7.35 (m, 10H, Ar-H), 6.31 (br.s, 2H, NH_2 , exchangeable with D_2O), 2.69 (s, 3H, CH_3). MS m/z (%): 468 (M^+ ; 12.6), 433 (17.6), 392 (37.4), 250 (100), 218 (46.7), 218 (47.4), 77 (33.7). Anal. Calcd. for $C_{21}H_{17}ClN_6OS_2$ (468.98): C 53.78; H 3.65; Cl 7.56; N 17.92; S 13.67. Found: C 53.80; H 3.66; Cl 7.53; N 17.91; S 13.65.

6-(((5-Chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene)amino)-3-phenyl-2-thioxo-2,3-dihydrothiazolo[4,5-*d*]pyrimidin-7(6*H*)-one **19**

A solution of compound **16** (0.16 g, 0.34 mmol) in a mixture of triethylorthoformate (3 ml) and acetic anhydride (3 ml) was heated under reflux for 9 h. After cooling, the solid deposited was collected by filtration and recrystallized from toluene to give **19** as off white crystals; m.p.: 258–259 °C, yield: 83%. IR (KBr): 2959, 2922, 2853 (CH_3), 1666 ($C=O_{pyrimidinone}$), 1592 ($C=N$), 1243 ($C=S$) cm^{-1} . 1H NMR (400 MHz, DMSO- d_6) δ (ppm): 9.31 (s, 1H, Ar- $H_{pyrimidinone}$), 8.22 (s, 1H, $HC=N$), 7.65–7.35 (m, 10H, Ar-H), 2.57 (s, 3H, CH_3). MS m/z (%): 478 (M^+ ; 8.4), 450 (12.2), 443 (23.9), 402 (19.8), 343 (35.4), 261 (24.1), 217 (66.3), 77 (100). Anal. Calcd. for $C_{22}H_{15}ClN_6OS_2$ (478.97): C 55.17; H 3.16; Cl 7.40; N 17.55; S 13.39. Found: C 55.19; H 3.14; Cl 7.41; N 17.52; S 13.36.

N'*-(5-Chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene)-2-cyano-3-mercapto-3-(phenylamino)acrylohydrazide **21*

To a stirred solution of potassium hydroxide (0.56 g, 0.01 mol) in DMF (20 ml) compound **3** (3.01 g, 0.01 mol) was added. After stirring for 30 min, phenyl isothiocyanate (1.2 ml, 0.01 mol) was added to the resulting mixture. Stirring was persistent at ambient temperature for 12 h. The reaction mixture was acidified with cold dilute HCl. The solid product that separated was filtered, washed with water, and recrystallized from benzene to give **21** as buff crystals; m.p.: 136–138 °C, yield: 72%. IR (KBr): 3273, 3194 (NH), 2958, 2925, 2853 (CH₃), 2225 (C≡N), 1676 (C=O), 1630 (C=N) cm⁻¹. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 12.70 (s, 1H, NH, exchangeable with D₂O), 10.53 (br.s, 1H, NH, exchangeable with D₂O), 8.06 (s, 1H, HC=N), 7.59–7.34 (m, 10H, Ar–H), 2.43 (s, 3H, CH₃), 1.21 (s, 1H, SH, exchangeable with D₂O). MS *m/z* (%): 436 (M.⁺; 0.9), 401 (1.1), 359 (20.3), 357 (100), 343 (23.5), 316 (5.7), 281 (8.4), 128 (9.6), 77 (24.2), 51 (7.5). Anal. Calcd. for C₂₁H₁₇ClN₆OS (436.92): C 57.73; H 3.92; Cl 8.11; N 19.24; S 7.34. Found: C 57.72; H 3.89; Cl 8.09; N 19.27; S 7.35.

N'*-(5-Chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene)-2-cyano-2-(5-oxo-3-phenylthiazolidin-2-ylidene)acetohydrazide **22*

To a stirred solution of potassium hydroxide (0.56 g, 0.01 mol) in DMF (20 ml) compound **3** (3.01 g, 0.01 mol) was added. After stirring for 30 min, phenyl isothiocyanate (1.2 ml, 0.01 mol) was added to the resulting mixture. Stirring was persistent at ambient temperature for 12 h, and then, chloroacetyl chloride (0.8 ml, 0.01 mol) was added and stirring was persistent for additional 6 h. The reaction mixture was acidified with cold dilute acetic acid. The separated solid was filtered off, washed several times with cold water, and recrystallized from toluene to give **22** as green crystals; m.p.: 140–142 °C, yield: 79%. IR (KBr): 3334 (NH), 2968, 2924, 2854 (CH₂, CH₃), 2195 (C≡N), 1745 (C=O_{thiazolidinone}), 1664 (C=O_{amide}), 1618 (C=N), 1595 (C=C) cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 9.03 (s, 1H, NH, exchangeable with D₂O), 7.99 (s, 1H, HC=N), 7.66–7.30 (m, 10H, Ar–H), 3.89 (s, 2H, CH₂S), 2.58 (s, 3H, CH₃). MS *m/z* (%): 259 (M.⁺–C₁₁H₉ClN₃; 100), 244 (29.4), 218 (17.9), 190 (4.7), 77 (7.9), 51 (4.9). Anal. Calcd. for C₂₃H₁₇ClN₆O₂S (476.94): C 57.92; H 3.59; Cl 7.43; N 17.62; S 6.72. Found: C 57.94; H 3.57; Cl 7.39; N 17.60; S 6.74.

N'*-(5-Chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene)-2-cyano-3-(ethylthio)-3-(phenylamino)acrylohydrazide **23*

To a stirred solution of potassium hydroxide (0.56 g, 0.01 mol) in DMF (20 ml) compound **3** (3.01 g, 0.01 mol) was added. After stirring for 30 min, phenyl isothiocyanate (1.2 ml, 0.01 mol) was added to the resulting mixture. Stirring was persistent at ambient temperature for 12 h, and then, ethyl iodide (0.62 ml, 0.01 mol) was added and stirring was persistent for additional 6 h. The reaction mixture was poured onto ice cold water, and the resulting precipitate was filtered off, washed several times with cold water and recrystallized from benzene to give **23** as reddish brown crystals; m.p.: 178–180 °C, yield: 71%. IR (KBr): 3275 (NH), 2963, 2925, 2858 (CH₂, CH₃), 2193 (C≡N), 1637 (C=O), 1621 (C=N), 1590 (C=C) cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 12.54 (s, 1H, NH, exchangeable with D₂O), 9.04 (s, 1H, NH, exchangeable with D₂O), 8.03 (s, 1H, HC=N), 7.54–7.28 (m, 10H, Ar–H), 2.65–2.60 (q, 2H, CH₂CH₃, *J* = 7.2), 2.54 (s, 3H, CH₃), 1.22–1.18 (t, 3H, CH₂CH₃, *J* = 7.6). MS *m/z* (%): 404 (M.⁺–C₂H₄S; 1.3), 389 (3.5), 369 (100), 354 (12.6), 339 (10.3), 77 (9.0), 51 (2.4). Anal. Calcd. for C₂₃H₂₁ClN₆OS (464.97): C 59.41; H 4.55; Cl 7.62; N 18.07; S 6.90. Found: C 59.39; H 4.53; Cl 7.64; N 18.11; S 6.89.

N'*-(5-Chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene)-2-cyano-2-(4-hydroxy-1,3-dithiol-2-ylidene)acetohydrazide **29*

To a stirred solution of potassium hydroxide (0.56 g, 0.01 mol) in DMF (20 ml), compound **3** (3.01 g, 0.01 mol) was added. After stirring for 30 min, the resulting mixture was cooled at 10 °C in an ice bath, and then, CS₂ (0.6 ml, 0.01 mol) was added slowly. Stirring was persistent for 12 h at ambient temperature, and then, chloroacetyl chloride (0.8 ml, 0.01 mol) and/or ethyl chloroacetate (1.07 ml, 0.01 mol) were added and stirring was persistent for additional 6 h. The reaction mixture was acidified with cold dilute acetic acid. The separated solid was filtered off, washed several times with cold water, and recrystallized from toluene to give **29** as brown crystals; m.p.: 254 °C, yield: 58%. IR (KBr): 3424 (OH), 3254 (NH), 2923, 2851 (CH₃), 2205 (C≡N), 1620 (br.s) (C=O), 1603 (C=N) cm⁻¹. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 11.83 (s, 1H, OH, exchangeable with D₂O), 9.89 (s, 1H, NH, exchangeable with D₂O), 8.63 (s, 1H, HC=N), 7.64–7.46 (m, 5H, Ar–H), 6.69 (s, 1H, HC=C), 2.43 (s, 3H, CH₃). MS *m/z* (%): 416 (M.⁺–1; 5.3), 399 (10.2), 375 (15.4), 218 (30.1), 200 (100), 77 (29.5). Anal. Calcd. for C₁₇H₁₂ClN₅O₂S₂ (417.89): C 48.86; H 2.89; Cl 8.48; N 16.76; S 15.34. Found: C 48.84; H 2.90; Cl 8.45; N 16.77; S 15.36.

Cytotoxicity and antitumor evaluation

Materials and methods

Cell lines Hepatocellular carcinoma (HepG-2) and mammary gland (MCF-7) were obtained from ATCC via Holding company for biological products and vaccines (VACSERA), Cairo, Egypt.

Chemical reagents The reagents RPMI-1640 medium, MTT, and DMSO (sigma co., St. Louis, USA), Fetal Bovine serum (GIBCO, UK).

Doxorubicin was used during comparison as a standard anticancer drug.

MTT assay The different cell lines mentioned above were used to determine the inhibitory effects of compounds on cell growth using the MTT assay [20, 21]. This colorimetric test is based on the change of the yellow tetrazolium bromide (MTT) to a purple formazan derivative by mitochondrial succinate dehydrogenase in viable cells. The cells were cultured in RPMI-1640 medium with 10% fetal bovine serum. Antibiotics added were 100 units/ml penicillin and 100 µg/ml streptomycin at 37 °C in a 5% CO₂ incubator. The cells were seeded in a 96-well plate at a density of (1.0 × 10⁴ cells/well) at 37 °C for 48 h under 5% CO₂. After incubation, the cells were treated with various concentrations of compounds and put in the incubator for 24 h; then, 20 µl of MTT solution at 5 mg/ml was added and incubated for 4 h. DMSO (100 µl) was added into each well to dissolve the purple formazan formed. At 570 nm absorbance, the colorimetric assay was measured and recorded using a plate reader (EXL 800, USA):

Calculation of the relative cell viability (%)

$$= (A \text{ of treated samples} / A \text{ of untreated sample}) \times 100.$$

Antioxidant assay

Antioxidant activity screening assay; ABTS method Determinations of antioxidant activities were estimated from the bleaching of ABTS-derived radical cations. The radical cation was derived from ABTS [2,2'-azino-bis(3-ethyl benzothiazoline-6-sulfonic acid)] was prepared by reaction of ABTS (60 µl) with MnO₂ (3 ml, 25 mg/ml) in phosphate buffer solution (10 µM, pH 7, 5 ml). After the solution was shaking for 3 min, centrifuged and filtered, the Absorbance $A_{(\text{control})}$ of the resulting ABTS radical solution (green-blue) was recorded at λ_{max} 734 nm. Upon the addition of (20 µl of 1 mg/ml) solution of the tested sample in spectroscopic grade MeOH/buffer (1:1 v/v) to the ABTS solution, the absorbance $A_{(\text{test})}$ was measured. The decrease in the absorbance is expressed as % inhibition which calculated from this equation [22]:

$$\% \text{Inhibition} = [A_{(\text{control})} - A_{(\text{test})} / A_{(\text{control})}] \times 100,$$

where the standard antioxidant (positive control) was ascorbic acid solution (20 µl, 2 mM) and blank sample was carried out by solvent without ABTS.

Antioxidant activity screening assay for erythrocyte hemolysis Rats' blood was obtained by cardiac puncture then collected in heparinized tubes. Separation of erythrocytes from plasma was occurred and the buffy coat was washed three times with ten volumes of 0.15 M NaCl. The erythrocytes were centrifuged in the last wash at 2500 rpm for 10 min to obtain a constantly packed cell preparation. In this assay [23], erythrocyte hemolysis was mediated by peroxy radicals. The erythrocytes were suspended in phosphate buffered saline (PBS) pH 7.4. The suspension (10%) was added to the same volume of 200 mM 2,2'-azobis(2-amidinopropane) dihydrochloride (AAPH) solution (in PBS) containing samples to be tested at various concentrations. The reaction mixture was shaken gently while being incubated at 37 °C for 2 h. Then diluted with eight volumes of PBS and centrifuged at 2500 rpm for 10 min. The absorbance A of the supernatant was recorded at 540 nm. Similarly, the reaction mixture was treated with eight volumes of distilled water to achieve complete hemolysis, and the absorbance B of the supernatant obtained after centrifugation was recorded at 540 nm:

Calculation of the percentage hemolysis = $(1 - A/B) \times 100\%$, where the data were indicated mean standard deviation and the positive control was L-ascorbic acid.


Results and discussion

Chemistry

Herein, we report the study of the reactions of the requisite 5-chloro-3-methyl-1-phenyl-1*H*-pyrazole-4-carbaldehyde **1** [24] with cyanoacetohydrazide **2** in different conditions to obtain variant products.

Condensation of pyrazole aldehyde derivative **1** with cyanoacetohydrazide **2** in boiling absolute ethanol and/or dioxane tolerated the hydrazide-hydrazone derivative **3**. During refluxing compound **3** in absolute ethanol containing a few drops of piperidine afforded the diarylidene hydrazine derivative **4** [25] as light brown crystal. The same product **4** was isolated and identified when the reaction executed in refluxing compound **1** with cyanoacetohydrazide **2** in ethanol containing a few drops of piperidine directly (Scheme 1).

Heterointra cyclization of compound **3** via refluxing it with glacial acetic acid for 10 h to give pyrazolinone derivative **5**, beside that the amide derivative **6** was obtained.



Scheme 1 Formation and reactions of compound **3** under different conditions




Fig. 1 Diastereomeric isomers of compound **3**



Thus, alternative synthetic route for pyrazolinone derivative **5** could be solely obtained in one step by the reaction of compound **1** with cyanoacetohydrazide **2** in boiling absolute ethanol containing a few drops of glacial acetic acid. On the other hand, refluxing of compound **3** in dry pyridine afforded **4** and **5**. Unfortunately, refluxing of compound **3** with anhydrous potassium carbonate in dry acetone, the diarylidene hydrazine derivative **4**, was obtained as the sole product instead of the desired pyrazolo[3,4-*c*]pyrazole **7** (Scheme 1).

Noteworthy, compound **4** was obtained when we used hard base such as piperidine and K_2CO_3 and borderline base as pyridine were classified according to HSAB theory (Pearson concept). Meanwhile, in the case of using hard acid as acetic acid, the cyclized pyrazolinone derivatives **5** and **6** were obtained.

The spectral and microanalytical data for compounds **3–6** were fit with their chemical structures. The structure of *N'*-((5-chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene)-2-cyanoacetohydrazide **3** was elucidated by elemental analysis and spectroscopic data. The IR spectrum showed the appearance of stretching absorption bands for ν_{NH} at 3192, 3126 cm^{-1} , $\nu_{C\equiv N}$ at 2263 cm^{-1} and $\nu_{C=O}$ at 1681 cm^{-1} . Furthermore, 1H NMR spectrum of **3** is in accordance with its proposed structure, as it showed signals for NH, methyl, methylene, methine, and aromatic protons. Compound **3** exists as a diastereomeric mixture (syn/anti) in the ratio 11.5:88.5. The higher ratio of the anti-isomer is due to its higher stability, since it underwent less steric hindrance because of both hetroaryl and cyanoacetamido groups in the opposite sides. The down field value for the signal of NH proton as well as the upfield value of the signal of imino methine (CH=N) proton of the anti-isomer may be attributed to extension of the conjugation as a result of coplanarity of hetroaryl group and $-NH-CO-CH_2CN$ moiety, as shown in Fig. 1.

The mechanistic scenarios for the formation of compounds **4–6** are illustrated, as shown in Scheme 2.

The 1H NMR spectrum of compound **6** in DMSO solution revealed the presence of four peaks exchangeable with

Scheme 2 Mechanistic pathways to compounds **4–6****Fig. 2** Diastereomeric mixture of compound **6**

D_2O at $\delta = 13.31, 12.20, 10.65$, and 10.40 ppm corresponding to OH, NH_2 , NH, and NH_2 , respectively. ^1H NMR of **6** revealed its existence as a diastereomeric mixture in the ratio of 51:49. The down field shifts of OH and NH_2 protons are



due to intramolecular chelated H-bond in six-membered ring (Fig. 2).

Focusing on reactivity of β -ketonitriles towards some nucleophilic and electrophilic agents led us to explore the utilization of the hydrazide-hydrazone derivative **3** as a precursor to construct more heterocycles.

Therefore, compound **3** was allowed to react with hydrazine hydrate to constructing pyrazole derivative **8**, as described in the literature [26, 27]. However, its reaction with hydrazine hydrate produced the diarylidene hydrazine derivative **4** instead of **8** (Scheme 3).

Plausible mechanistic pathways to demonstrate the formation of compound **4** is illustrated in Scheme 4. The pathway **b** was extrapolated from the anterior mechanism.


The proclivity of **3** towards some electrophilic reagents such as aromatic aldehydes, heterocyclic ketone, aliphatic

Scheme 3 Hydrazinolysis of compound **3****Scheme 4** Mechanistic illustration of **4** formation

ketone, arylidene malononitrile, and phenyl isothiocyanate was also investigated as follow in Scheme 5.


In our previous work [17, 18], when β -ketonitrile was refluxed with *p*-nitrobenzaldehyde in boiling ethanol in the presence of piperidine, the corresponding condensation product **9** was afforded (Scheme 5). Meanwhile, in this

study, the diarylidene hydrazine derivative **4** was obtained instead. As an alternative way, when a harder base such as sodium ethoxide used at room temperature instead of piperidine, the reaction was smoothly achieved to afford **9** (Scheme 5). The IR spectrum of compound **9** exhibited stretching absorption bands at 2210 cm^{-1} ($\text{C}\equiv\text{N}$) and 1680 ,



Scheme 5 Synthetic pathway to compounds **9–13**

Fig. 3 Lactam–lactim tautomers of compound **9**



1668 cm^{−1} (C=O). Moreover, IR spectrum indicated the presence of the nitro group by displaying two bands due to asymmetrical and symmetrical stretching bands at 1529 and 1346 cm^{−1}. In DMSO solution, the ¹H NMR spectrum of compound **9** exhibited two singlet signals for NH and OH protons properly represented to its existence as a lactam–lactim dynamic equilibrium in the ratio of 39:61. The higher proportion of the lactim tautomer is due to its more conjugated pattern, as shown in Fig. 3.


Unfortunately, hydrazinolysis of the condensation product **9** in boiling ethanol yielded the diarylidene hydrazine derivative **4** rather than the desired pyrazole derivative **10** [28] (Scheme 5).

Refluxing of an ethanolic solution of isatin with the active methylene group of compound **3** afforded **11** in good

yield as dark brown crystals (Scheme 5). The structure **11** was substantiated from the microanalytical and spectroscopic data.

The synthesis of 4,6-dimethyl pyridinone derivative **12** was commenced from the reaction of cyanoacetamide **3** with acetylacetone in ethanolic solution containing drops of piperidine. As a proof for the proposed structure of **12**, ¹H NMR spectrum of **12** showed characteristics singlet peaks for HC=N, CH_{pyridinone}, CH_{3pyrazole}, and two CH_{3pyridinone} at δ=8.76, 6.39, 2.47, 2.346, and 2.343 ppm, respectively, besides multiplet peak for Ph at δ=7.62–7.51 ppm.

Heating a mixture of compound **3** with 2-(3,4-dimethoxybenzylidene)malononitrile in absolute ethanol containing a catalytic amount of piperidine afforded 6-amino-2-oxo-1,2,3,4-tetrahydropyridine derivative **13** (Scheme 5). The



Scheme 6 Synthetic pathway to compounds **15a,b–19**

proposed structure of **13** was confirmed by spectral and elemental analyses.

Following the same literately reported a synthesis of iminocoumarin derivatives [17, 18], herein, novel iminocoumarin derivatives were built upon refluxing compound **3** with an ethanolic solution of salicylaldehyde and/or 3,5-dinitrosalicylaldehyde **14a,b** (1:1 molar ratio) in the presence of a catalytic amount of piperidine. (Scheme 6).

The structures of iminocoumarin derivatives **15a,b** were unambiguously ascertained on the basis of analytical and spectroscopic data. For example, the IR spectrum of **15a** displayed ν_{NH} at 3312 cm^{-1} , $\nu_{\text{C=O}}$ at 1682 cm^{-1} and $\nu_{\text{C=N}}$ at 1632 cm^{-1} . At the same time, the IR spectrum of **15b** displayed ν_{NH} at 3206 cm^{-1} , $\nu_{\text{C=O}}$ at 1683 cm^{-1} , $\nu_{\text{C=N}}$ at 1619 cm^{-1} and ν_{NO_2} at 1550 and 1339 cm^{-1} , it is also worthy to mentioned that IR of both compounds showed the absence of a stretching absorption band for nitrile group.

Afterwards, compounds **15a,b** were individually refluxed with triethyl orthoformate in the presence of distilled acetic anhydride to afforded **16** and **17a,b** (Scheme 6).

Characterizations of the newly synthesized compounds **16**, **17a,b** were based on spectral and elemental analyses.


The IR spectrum of compound **16** refers to the existence of an aldehydic carbonyl group at 1710 cm^{-1} . Moreover, the ^1H NMR spectrum indicated the presence of a singlet peak at δ 8.83 ppm (aldehydic proton).

For compounds **17a,b**, the IR spectrum showed the presence of a stretching absorption band for the carbonyl groups at 1719 and 1678 cm^{-1} . As well, the ^1H NMR spectrum revealed the existence of a mixture of the two compounds **17a,b** due to the presence of methine proton as singlet at δ 5.83 ppm and ethoxy protons as quartet and triplet at 3.66–3.56 and 1.01 ppm, respectively. Besides, the presence of aldehydic proton as singlet peak at δ 9.03 ppm.

Refluxing a three component, an ethanolic mixture of **3** with phenyl isothiocyanate and elemental sulfur afforded 2-thioxo-2,3-dihydrothiazole derivative **18** under basic condition (Et_3N) (Scheme 6).

The structure of **18** was unequivocally proven via investigating the IR spectrum which exhibited the absence of cyano group. Furthermore, ^1H NMR displayed broad singlet at δ 6.31 ppm exchangeable with D_2O corresponding to NH_2 protons.

2-Thioxo-2,3-dihydrothiazolo[4,5-*d*]pyrimidin-7(6*H*)-one derivative **19** was furnished when **18** was subjected to react

Scheme 7 Synthetic pathway to compounds **21–23**

with triethyl orthoformate in the presence of distilled acetic anhydride (Scheme 6). The proposed structure of **19** was confirmed by spectral and elemental analyses. In particular, ¹H NMR spectrum of **19** showed a characteristic peak for CH_{pyrimidinone} at δ 9.31 ppm and the absence of peak of NH₂ protons.

The reactivity of the active methylene moiety of compound **3** was investigated. Thus, when compound **3** was allowed to react with phenyl isothiocyanate in dry DMF containing a catalytic amount of potassium hydroxide at room temperature [18, 19], it yielded the nonisolable intermediate potassium sulfide salt **20**, followed by acidification with dilute HCl to isolate compound **21** in good yield (Scheme 7). The microanalytical and spectroscopic data were in agreement with the proposed structure **21**.

Otherwise, treatment of the nonisolable potassium sulfide salt **20** in situ with chloroacetyl chloride afforded 1,3-thiazolidin-5-one derivative **22** (Scheme 7). Supposedly, the reaction mechanism is assumed to proceed via S-acylation followed by closure of the thiazole ring upon N-alkylation of the remaining CH₂Cl group to award thiazolidinone derivative **22**. Elemental analyses and spectral data were in favor of this proposed 1,3-thiazolidin-5-one structure. The IR spectrum of **22** showed absorption band at 1745 cm⁻¹ due to carbonyl group of the thiazolidinone ring. The structure of **22** was also ascertained from ¹H NMR


spectrum of **22** which revealed the presence of a singlet peak at δ = 3.89 ppm corresponding to CH₂ protons of the thiazolidinone ring.

Moreover, curing of the nonisolable potassium sulfide salt **20** with ethyl iodide afforded *N'*-((5-chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene)-2-cyano-3-(ethylthio)-3-(phenylamino)acrylohydrazide **23** (Scheme 7).

Unfortunately, when the novel ketene *N,S*-acetal **23** was refluxed with hydrazine hydrate in ethanol, the sulfur-free compound which was characterized as the diarylidene hydrazine derivative **4** was obtained as the sole product instead of the desired pyrazole derivative **24** [19]. No clue for the formation of 3-aminopyrazole derivative **24** was detected neither from spectroscopic nor elemental analyses (Scheme 7).

Finally, compound **3** with carbon disulfide in the presence of potassium hydroxide in DMF afforded the intermediate dipotassium dithiolate salts **25** which in situ underwent S-acylation with chloroacetyl chloride and/or S-alkylation with ethyl chloroacetate as different intermediates **26** and **27**, respectively. In both cases, the 4-oxo-1,3-dithiolane derivative **28** was anticipated. However, unexpectedly, its enol tautomer **29** was obtained instead. The chemical structure of **29** was supported on the basis of elemental analysis and spectral data (Scheme 8).

Scheme 8 Synthetic pathways to 4-hydroxy-1,3-dithiole derivative **28**



Pharmacology

Cytotoxicity and antitumor evaluation

Out of the newly synthesized compounds, 14 analogs were selected to be evaluated for their in-vitro anticancer effects via the standard MTT method [20, 21], against a panel of two human tumor cell lines; (HepG2) hepatocellular carcinoma and (MCF-7) mammary gland breast cancer. Doxorubicin was used during comparison as a standard anticancer drug. The results of cytotoxic activity of compounds are summarized in Table 1 and Fig. 4.

The obtained results revealed that the tested compounds, namely, **4**, **6**, **9**, **11**, **13**, **15a**, **15b**, **16**, **18**, **19**, **21**, **22**, **23**, and **29** exhibited variable degrees of inhibitory activity towards the two tested human tumor cell lines. As for activity against HepG2, the very strongest cytotoxic activity was exhibited by compounds **13** and **29** which showed the percentage viability IC_{50} at 6.48 ± 0.6 and 9.16 ± 0.9 μM ,

respectively. Whereas, the strongest cytotoxic activity was exhibited by compounds **6**, **11**, and **22** which showed the percentage viability IC_{50} at 15.90 ± 1.4 , 19.02 ± 1.6 , and 11.79 ± 1.2 μM , respectively. Meanwhile, compounds **15a**, **15b**, **4**, and **18** showed moderate activity, while other compounds showed weak activities. On the other hand, the activity against MCF-7 cell line revealed that compounds **13** and **29** have the very highest percentage viability IC_{50} at 5.48 ± 0.4 and 8.26 ± 0.7 μM , respectively. Both compounds **6** and **22** showed the strongest activities. Whereas, compounds **4**, **11**, **15a**, **15b**, and **18** showed moderate activities. Meanwhile, the other tested compounds exhibited weak activities.


Structure activity relationships (SARs) By comparing the cytotoxicity assessment of the reported compounds, in this study, we conclude the following essential structural features for activity enhancement.

Table 1 Cytotoxic activity of some new compounds against human tumor cells

Compounds	In-vitro cytotoxicity IC ₅₀ (μM)	
	HepG2	MCF-7
DOX	4.50 ± 0.3	4.17 ± 0.2
4	43.41 ± 2.8	48.03 ± 3.0
6	15.90 ± 1.4	12.71 ± 1.1
9	52.96 ± 3.4	61.34 ± 4.1
11	19.02 ± 1.6	23.34 ± 1.8
13	6.48 ± 0.6	5.48 ± 0.4
15a	31.74 ± 2.3	35.82 ± 2.5
15b	36.22 ± 2.5	40.85 ± 2.8
16	69.53 ± 3.9	72.82 ± 4.5
18	24.86 ± 1.9	29.28 ± 2.2
19	64.78 ± 3.7	58.96 ± 3.6
21	83.45 ± 4.8	91.75 ± 5.2
22	11.79 ± 1.2	18.36 ± 1.5
23	74.63 ± 4.2	51.40 ± 3.4
29	9.16 ± 0.9	8.26 ± 0.7


IC₅₀ (μM): 1–10 (very strong), 11–20 (strong), 21–50 (moderate), 51–100 (weak) and above 100 (non-cytotoxic)

DOX Doxorubicin


**Fig. 4** Cytotoxic activity of some new compounds against human tumor cells

- (1) The presence of pyrazole skeleton is necessary for the broadening of cytotoxic activity towards both cell lines (HepG2 and MCF-7).
- (2) Since compound **13** has a remarkable potency closer to doxorubicin against both cell lines (HepG2 and MCF-7) which may be attributed to the presence of 3,4-dihydropyridinone moiety, beside incorporating of amino and two methoxy groups (electron donating groups).
- (3) 4-Hydroxy-1,3-dithiole ring in **29** enhances the antitumor activity against both cell lines.

ABTS method

**Fig. 5** Antioxidant activity of some new compounds by ABTS method

Erythrocyte haemolysis

**Fig. 6** Antioxidant activity of some new compounds by erythrocyte hemolysis method**Table 2** Antioxidant activity of some new compounds by ABTS method

Method	ABTS	
	$\frac{\text{Abs}_{(\text{control})} - \text{Abs}_{(\text{test})}}{\text{Abs}_{(\text{control})}} \times 100$	
Compounds	Absorbance of samples	% Inhibition
Control of ABTS	0.525	–
Ascorbic acid	0.061	88.4
4	0.408	22.3
6	0.332	36.8
9	0.409	22.1
11	0.363	30.8
13	0.262	50.1
15a	0.404	23.0
15b	0.406	22.7
16	0.411	21.7
18	0.384	26.8
19	0.410	21.9
21	0.419	20.2
22	0.281	46.5
23	0.412	21.5
29	0.281	46.5

Table 3 Antioxidant activity of some new compounds by erythrocyte hemolysis method

Method	Erythrocyte hemolysis $A/B \times 100$	
Compounds	Absorbance of samples	% Hemolysis
Absorbance of H ₂ O (B)	0.850	—
Vit-C	0.031	3.64
4	0.031	3.64
6	0.033	3.88
9	0.039	4.58
11	0.034	4.00
13	0.031	3.64
15a	0.043	5.05
15b	0.042	4.94
16	0.034	4.00
18	0.046	5.41
19	0.038	4.47
21	0.032	3.76
22	0.034	4.00
23	0.046	5.41
29	0.031	3.64

- (4) Cyclization of compound **3** into 4,5-dihydropyrazolone derivative **6** incorporating amide group in position 4 enhances the antitumor activity against both cell lines.
- (5) Introduction of indolin-2-one moiety into compound **11** increases the antitumor activity against HepG2 cell line.
- (6) Compound **22** is more potent than **21** and **23** which may be due to conversion of compound **3** into 1,3-thiazolidin-5-one moiety.
- (7) Compound **16** is less potent than compound **15a** which may be attributed to the conversion of the iminocoumarin into *N*-formyl moiety. In addition, compound **19** is less potent than compound **18** which may be attributed to the conversion of 4-amino thiazol-2-thione into 2-thioxo-2,3-dihydrothiazolo[4,5-*d*]pyrimidin-7(6*H*)-one moiety. As a conclusion, it is obvious that in these two cases, disappearance of NH and NH₂ diminishes the potency which could be refused to declining in hydrophobicity character.

Antioxidant activity screening

The newly synthesized compounds were selected and screened for antioxidant activity. Antioxidant effects of the compounds were screened using ABTS assay. Compounds **13**, **22**, and **29** displayed promising activities. In the meantime, compounds **6** and **11** showed moderate activities.

In case of erythrocytes hemolysis, compounds **4**, **13**, and **29** proved to exhibit potent antioxidative activity as vitamin C, while compounds **6**, **11**, **16**, **21**, and **22** showed very high activities.

From Tables 2 and 3 and Figs. 5 and 6 and the above-mentioned results, we may include the following structure activity relationships (SARs).

- (1) The presence of 3,4-dihydropyridinone, 1,3-thiazolidin-5-one and 4-hydroxy-1,3-dithiole moieties in compounds **13**, **22**, and **29**, respectively, besides the incorporation of pyrazole ring bearing methyl, phenyl groups, and chlorine atom proved to be vital for remarkable potential inhibitory antioxidant activity using ABTS method.
- (2) Introduction of heterocyclic moieties as in compounds **4**, **13**, and **29** enhanced the antioxidant activity in erythrocytes hemolysis to the same extent of vitamin C. Those compounds are currently under more evaluation as a potential candidate drugs.

Literately, some previous reports showed that structurally similar but they are different in pyrazole moiety which manifested different results in antitumor and antioxidant activities than our results [17, 29].

Conclusion

The goal of the present study is too utilizing some pyrazole derivatives as scaffold for constructing different heterocyclic moieties on it. As an ultimate goal, those synthesized compounds were screened and evaluated as potent agents against the antitumor and antioxidant activity. The data collection showed clearly that compounds **6**, **11**, **13**, **22**, and **29** displayed promising in-vitro antitumor activity against two cell lines (HepG2 and MCF-7). Among these compounds, compounds **13** and **29** exhibited broad spectrum of antitumor agent. On the other hand, compounds **13**, **22**, and **29** exhibited the highest inhibitory antioxidant activity using ABTS method. Meanwhile, in case of erythrocytes hemolysis, compounds **4**, **13**, and **29** proved to exhibit potent antioxidative activity as vitamin C. Noteworthy, Compounds **13** and **29** manifested the highest potency in targeting both antitumor and antioxidant activities.

References

1. S. Viveka, P. Dinesha, S. Shama, N.K. Naveen, G.K. Lokanath, Nagaraja, RSC Adv. **5**, 94786 (2015)
2. H.M. Faidallah, M.M. Al-Mohammadi, K.A. Alamry, K.A. Khan, J. Enzym. Inhib. Med. Chem. **31**, 157 (2016)

3. S. Ghadbeigi, S.N. Ostad, A. Shafiee, M. Amini, *Lett. Drug Des. Discov.* **12**, 754 (2015)
4. S.G. Alegaon, K.R. Alagawadi, M.K. Garg, K. Dushyant, D. Vinod, *Bioorg. Chem.* **54**, 51 (2014)
5. H.V. Chavan, B.P. Bandgar, L.K. Adsul, V.D. Dhakane, P.S. Bhale, V.N. Thakare, V. Masand, *Bioorg. Med. Chem. Lett.* **23**, 1315 (2013)
6. D.C. Malvar, R.T. Ferreira, R.A. de Castro, L.L. de Castro, A.C.C. Freitas, E.A. Costa, I.F. Florentino, J.C.M. Mafra, G.E.P. de Souza, F.A. Vanderlinde, *Life Sci.* **95**, 81 (2014)
7. M. Jyothi, R. Merugu, *Int. J. Pharm. Tech. Res.* **8**, 80 (2015)
8. K.P. Beena, A.A.A. Elkhider, P. Shebina, V. Sindhuja, *J. Chem. Pharm. Res.* **8**, 915 (2016)
9. S. Du, Z. Tian, D. Yang, X. Li, H. Li, C. Jia, C. Che, M. Wang, Z. Qin, *Molecules* **20**(5), 8395 (2015)
10. C.R. Fu, J. Pei, Y. Ning, M. Liu, P.C. Shan, J. Liu, Y.Q. Li, F.Z. Hu, Y.Q. Zhu, H.Z. Yang, *Pest Manag. Sci.* **70**, 1207 (2014)
11. H. Wu, J.-T. Feng, K.-C. Lin, X. Zhang, *Molecules* **17**, 12187 (2012)
12. R. Perez-Fernandez, P. Goya, J. Elguero, *Arkivoc* **2**, 233 (2014)
13. Z. Hajizadeh, A. Maleki, *Mol. Catal.* **460**, 87 (2018)
14. A. Maleki, A.A. Jafari, S. Yousefi, *Carbohydr. Polym.* **175**, 409 (2017)
15. A. Shaabani, M. Seyyedhamzeh, A. Maleki, M. Behnam, F. Rezaadeh, *Tetrahedron Lett.* **50**, 2911 (2009)
16. A.A. Fadda, M.M. Mukhtar, M.R. Hala, *Am. J. Org. Chem.* **2**(2), 32 (2012)
17. M.F. Ismail, G.A. El-sayed, *Synth. Commun.* **48**, 892 (2018)
18. M.R. Mahmoud., S.A. Shiba, A.K. El-Ziaty, F.S.M. Abu El-Azm, M.F. Ismail, *Synth. Commun.* **44**, 1094 (2014)
19. M.R. Mahmoud, A.K. El-Ziaty, F.S.M. Abu El-Azm, M.F. Ismail, S.A. Shiba, *J. Chem. Res.* **37**, 80 (2013)
20. T. Mosmann, *J. Immunol. Methods* **65**(1–2), 55 (1983)
21. F. Denizot, R. Lang, *J. Immunol. Methods* **89**(2), 271 (1986)
22. E.A. Lissi, B. Modak, R. Torres, J. Escobar, A. Urzua, *Free Radic. Res.* **30**, 471 (1999)
23. Y. Morimoto, K. Tanaka, Y. Iwakiri, S. Tokuhira, S. Fukushima, Y. Takeuchi, *Biol. Pharm. Bull.* **18**(10), 1417 (1995)
24. Y.-Q. Cun-Jin, Shi, *J. Chem. Crystallogr.* **41**, 1816 (2011)
25. F.M. Abd El-Latif, M.A. Barsy, E.A. Elrady, M. Hassan, *J. Chem. Res. (S)* **12**, 696 (1999)
26. N. Suryakiran, D. Ramesh, Y. Venkateswarlu, *Green Chem. Lett. Rev.* **1**(1), 73 (2007)
27. T.P. Larry, M.C. Michael, O.M. Florence, *Tetrahedron* **67**, 4601 (2011)
28. M. Rafat, Z. Jonathan, A.M. Abeer, *Phosphorus Sulfur Silicon Relat. Elem.* **182**, 1661 (2007)
29. W.W. Wardakhan, S.M. Sherif, R.M. Mohareb, A.S. Abouzied, *Int. J. Org. Chem.* **2**, 321 (2012)

Affiliations

Mahmoud F. Ismail¹  · Amira A. El-sayed¹

✉ Mahmoud F. Ismail
fawzy2010@sci.asu.edu.eg

¹ Department of Chemistry, Faculty of Science, Ain Shams University, Cairo, Abbassia 11566, Egypt